Chi-Med and BeiGene Collaborate to Evaluate the Combinations of Surufatinib and Fruquintinib with Tislelizumab for Solid Tumors

Shots:

• The two companies collaborated to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib and fruquintinib, with BeiGene’s tislelizumab against multiple solid tumor cancer indications in the US, EU, China and Australia. Both the companies will mutually supply drug and other support
• Tislelizumab is an anti PD-1 mAb, specifically designed to minimize binding to FcγR, which is believed to play an essential role in activating phagocytosis in macrophages, to minimize its negative impact on T effector cells while fruquintinib improves kinase selectivity against VGEFR to minimize off-target toxicities
• Surufatinib is a VEGFR inhibitor, inhibits CSF-1R, blocks the accumulation of tumor-associated macrophages and promoting infiltration of T effector cells into tumors, leading to possible synergistic anti-tumor activity with PD-1 inhibitors

Click here to­ read full press release/ article | Ref: Business wire | Image: BeiGene